Evidence map›Paper›PMID 26466118›Full record

ArticlePloS one2015

Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study.

Cynthia Wu, Michael Sean McMurtry, Roopinder K Sandhu, Erik Youngson, Justin A Ezekowitz, Padma Kaul, Finlay A McAlister

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Regional disparities in the care and outcomes of atrial fibrillation patients in a universal health care system: a population-based cohort study.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Social determinants of atrial fibrillation.Nature reviews. Cardiology · 2021
    Review
  8. Direct oral anticoagulants uptake and an oral anticoagulation paradox.British journal of clinical pharmacology · 2020
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cynthia WuDepartment of Medicine, Division of Hematology, University of Alberta, Edmonton, Alberta, Canada.
Michael Sean McMurtryDepartment of Medicine, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada.
Roopinder K SandhuDepartment of Medicine, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada.
Erik YoungsonPatient Health Outcomes Research and Clinical Effectiveness Unit, University of Alberta, Edmonton, Alberta, Canada.
Justin A EzekowitzDepartment of Medicine, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada; Canadian VIGOUR Center, University of Alberta, Edmonton, Alberta, Canada.
Padma KaulDepartment of Medicine, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada.
Finlay A McAlisterPatient Health Outcomes Research and Clinical Effectiveness Unit, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, Division of General Internal Medicine, University of Alberta, Edmonton, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeWe studied whether anticoagulant use and outcomes differed between rural versus urban Canadian non-valvular atrial fibrillation (NVAF) patients prior to the introduction of direct oral anticoagulant drugs.

methodsRetrospective cohort study of 25,284 adult Albertans with NVAF between April 1, 1999 and December 31, 2008.

resultsCompared to urban patients, rural patients were older (p = 0.0009) and had more comorbidities but lower bleeding risk at baseline. In the first year after NVAF diagnosis, urban patients were less likely to be hospitalized (aOR 0.82, 95%CI 0.77-0.89) or have an emergency department visit for any reason (aOR 0.61, 95%CI 0.56-0.66) but warfarin dispensation rates (72.2% vs 71.8% at 365 days, p = 0.98) and clinical outcomes were similar: 7.8% died in both groups, 3.2% rural vs. 2.8% urban had a stroke or systemic embolism (SSE) (aOR 0.92, 95%CI 0.77-1.11), and 6.6% vs. 5.7% (aOR 0.93, 95%CI 0.81-1.06) had a bleed. Baseline SSE risk did not impact warfarin dispensation (73.0% in those with high vs. 72.8% in those with low CHADS2 score, p = 0.85) but patients at higher baseline bleeding risk were less likely to be using warfarin (69.2% high vs. 73.6% low HASBLED score, p<0.0001) in the first 365 days after diagnosis. In warfarin users, bleeding was more frequent (7.5% vs 6.2%, aHR 1.51 [95%CI 1.33-1.72]) but death or SSE was less frequent (7.0% vs 18.1%, aHR 0.60 [0.54-0.66]).

conclusionWarfarin use and clinical event rates did not differ between rural and urban NVAF patients in a universal access publically-funded healthcare system.

Indexed as

Rural PopulationAgedAged, 80 and overAmbulatory Care FacilitiesAnticoagulantsAtrial FibrillationCanadaCohort StudiesComorbidityEmbolismFemaleHospitalizationHumansMaleOdds RatioPatient Outcome AssessmentAnticoagulantsWarfarin

Identifiers

PMID26466118
PMCPMC4605516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.